Monia Vial
About
Monia Vial serves as Head of the U.S. Rare Diseases Business Unit at Ipsen, with responsibility for the commercial strategy, performance, and growth of a multi-brand portfolio in rare Disease. In this role, she leads large cross-functional sales and marketing organizations with full P&L accountability and oversees multiple launches across rare disease indications. Under her leadership, Ipsen continues to strengthen patient access to innovative therapies while driving sustainable business growth.
Since joining Ipsen in 2018, Monia has held a series of increasingly senior leadership roles across oncology and rare diseases in the United States. Most recently, she served as Head of U.S. Solid Tumors Marketing, where she defined the franchise vision and strategy, led lifecycle management for key oncology brands, and drove launch readiness for a first-line metastatic pancreatic cancer indication. Previously, Monia was Head of U.S. Oncology Strategy, shaping long-term franchise strategy and overseeing lifecycle and operational planning for one of Ipsen’s flagship products.
Earlier at Ipsen, Monia led New Products and Rare Diseases Commercial, playing a pivotal role in the company’s growth through business development and pipeline expansion.
Prior to Ipsen, Monia spent more than a decade at Shire Pharmaceuticals in global and regional commercial leadership roles across rare hematology, nephrology, and specialty care. Highlights include leading global commercial strategy, driving a turnaround to sustained growth in highly competitive markets, and overseeing multiple international launches. Earlier in her career, Monia held roles of increasing responsibility at Bristol Myers Squibb, AstraZeneca, and in pharmaceutical consulting, gaining broad experience across oncology, cardiovascular, and specialty markets.
Monia holds a Doctor of Pharmacy (PharmD) degree from the University of Pharmacy in Paris and a master’s degree in marketing from HEC Paris. She is trilingual in English, French, and Arabic and brings extensive international experience across the U.S. and Europe, with a proven track record of building high-performing teams, shaping strategy, and delivering strong commercial execution.
Since joining Ipsen in 2018, Monia has held a series of increasingly senior leadership roles across oncology and rare diseases in the United States. Most recently, she served as Head of U.S. Solid Tumors Marketing, where she defined the franchise vision and strategy, led lifecycle management for key oncology brands, and drove launch readiness for a first-line metastatic pancreatic cancer indication. Previously, Monia was Head of U.S. Oncology Strategy, shaping long-term franchise strategy and overseeing lifecycle and operational planning for one of Ipsen’s flagship products.
Earlier at Ipsen, Monia led New Products and Rare Diseases Commercial, playing a pivotal role in the company’s growth through business development and pipeline expansion.
Prior to Ipsen, Monia spent more than a decade at Shire Pharmaceuticals in global and regional commercial leadership roles across rare hematology, nephrology, and specialty care. Highlights include leading global commercial strategy, driving a turnaround to sustained growth in highly competitive markets, and overseeing multiple international launches. Earlier in her career, Monia held roles of increasing responsibility at Bristol Myers Squibb, AstraZeneca, and in pharmaceutical consulting, gaining broad experience across oncology, cardiovascular, and specialty markets.
Monia holds a Doctor of Pharmacy (PharmD) degree from the University of Pharmacy in Paris and a master’s degree in marketing from HEC Paris. She is trilingual in English, French, and Arabic and brings extensive international experience across the U.S. and Europe, with a proven track record of building high-performing teams, shaping strategy, and delivering strong commercial execution.
